|Day's Range||161.72 - 167.85|
|52 Week Range||71.46 - 167.86|
|PE Ratio (TTM)||225.90|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
ertex Pharmaceuticals’ Orkambi also secured U.S. Food and Drug Administration’s (or FDA) approval for CF patients in the age group of six to 11 years in September 2016.
Vertex Pharmaceuticals’ (VRTX) drugs, Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor), are capable of treating around 30,000 cystic fibrosis (or CF) patients.
A Couple of Healthy Companies to Consider.